Lipocine Inc. — Q3 2015 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2015. Unaudited results. Lipocine is a clinical-stage specialty pharmaceutical company developing oral therapies; it had no product-sales revenue and reported operating losses.
Financial results and position
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Research and development expense | $4.73 million | $3.25 million | $9.81 million | $12.59 million |
| General and administrative expense | $1.70 million | $0.87 million | $3.87 million | $3.83 million |
| Total operating expenses / operating loss | $6.43 million | $4.12 million | $13.69 million | $16.42 million |
| Net loss | $6.37 million | $4.09 million | $13.57 million | $16.33 million |
| Basic and diluted loss per share | $0.35 | $0.32 | $0.86 | $1.28 |
| Operating cash used | Not separately stated | Not separately stated | $12.44 million | $13.34 million |
- Revenue and margins: No product-sales revenue was reported; the filing does not provide a clear current-period revenue figure in the statements presented. Profit margins are not meaningful for this loss-making development-stage business.
- Liquidity: At September 30, cash and cash equivalents were $23.93 million, and marketable securities totaled $23.90 million, for combined cash, cash equivalents and securities of approximately $47.8 million. Current assets were $42.29 million and current liabilities $2.18 million.
- Debt: No debt or credit facility is reported; total liabilities were $2.18 million, consisting of current liabilities.
- Equity and cash flows: The April 2015 common-stock offering generated $32.4 million net proceeds. Investing cash use was $24.01 million, primarily from security purchases; financing provided $32.72 million. Cash and cash equivalents decreased $3.74 million during the nine-month period. Accumulated deficit was $81.8 million.
Material changes versus comparable periods
- Q3 operating expenses rose $2.32 million year over year and net loss widened by $2.28 million. R&D increased $1.49 million, reflecting a one-time $2.3 million FDA NDA filing fee, partly offset by lower clinical research, consulting and manufacturing costs as the Phase 3 study concluded. G&A rose $0.83 million, mainly from personnel, market research and pre-commercialization activity.
- For the first nine months, operating expenses fell $2.73 million and net loss improved $2.76 million year over year. Lower clinical, consulting and manufacturing costs after completion of the LPCN 1021 Phase 3 study more than offset the NDA filing fee. Nine-month G&A was broadly unchanged.
- Cash and cash equivalents declined from $27.67 million at year-end 2014 to $23.93 million, while marketable securities—none held at year-end—were $23.90 million at September 30, 2015. The company raised equity and increased its share count through the offering.
Outlook, programs and risks
- LPCN 1021: The FDA accepted the NDA in October 2015 and set a June 28, 2016 PDUFA goal date. The filing reported that the FDA’s 74-day filing communication did not mention an advisory committee. Management expected approximately $9.0 million of additional LPCN 1021 R&D costs for review-related work and launch-supply preparation; timing and cost remain uncertain.
- The completed SOAR Phase 3 study met the stated FDA primary efficacy guideline: 87% of subjects in the primary efficacy population achieved testosterone levels within the normal range, with a lower 95% confidence bound of 82%. Management reported 52-week tolerability and no hepatic, cardiac or drug-related serious adverse events in the trial. Approval is not assured; additional FDA requests, labeling limits or post-approval cardiovascular studies could add cost or delay commercialization.
- Pipeline: LPCN 1111 was in Phase 2, with a Phase 2b dose-finding study expected to begin in Q4 2015. LPCN 1107 was in Phase 1; a multi-dose PK dose-selection study had begun, with targeted completion in Q1 2016. The FDA’s eventual development requirements for LPCN 1107 remained uncertain.
- Management said existing capital resources were expected to fund projected operating requirements for at least the next 12 months, but additional capital may be needed. The company had no committed financing and warned that financing may be unavailable or dilutive; it expected losses and expenses to continue increasing.
- Litigation and other contingencies: On November 2, 2015, Clarus Therapeutics sued Lipocine, alleging that filing the LPCN 1021 NDA infringed Clarus’s patent and seeking damages and declaratory and injunctive relief. Lipocine said it intended to defend the case. Lipocine had also requested a patent interference concerning the patent. No litigation contingency was accrued at September 30; management did not consider any contingency probable and estimable.
- Other material risks include dependence on third-party manufacturer Encap for LPCN 1021 capsules while a commercial supply agreement was still under negotiation; possible generic testosterone-gel pricing and reimbursement pressure; regulatory uncertainty for testosterone therapies; and the need to build sales and marketing capabilities. The filing reports no off-balance-sheet arrangements and says disclosure controls were effective.
Important facts for investors to verify
- Subsequent FDA communications, review status, labeling, advisory-committee requirements and the June 28, 2016 PDUFA outcome for LPCN 1021.
- Progress and financial impact of the Clarus patent lawsuit and Lipocine’s patent-interference request.
- Execution of a commercial supply agreement with Encap, manufacturing readiness and the actual cost of launch preparation.
- Cash burn, investment-security liquidity and whether additional financing or commercialization partnerships will be required.
- Progress and spending on LPCN 1111 and LPCN 1107, including any changes to the expected study timelines or FDA development requirements.